Amylyx Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Amylyx together

Penke I guess you are interested in Amylyx Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Amylyx Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Amylyx Pharmaceuticals Inc

I send you an email if I find something interesting about Amylyx Pharmaceuticals Inc.

Quick analysis of Amylyx (30 sec.)

1. Valuation of Amylyx (5 min.)

Live pricePrice per share (EOD)

$25.56

Book Value per Share

$4.98

2. Growth of Amylyx (5 min.)

Is Amylyx growing?

	Current year	Previous year	Grow	Grow %
How rich?	$352.6m	$34.5m	$222.9m	86.6%

How much money is Amylyx making?

	Current year	Previous year	Grow	Grow %
Making money	-$37.2m	-$46m	$8.8m	?
Net Profit Margin	-3,943.6%	0.0%	-	-

How much money comes from the company's main activities?

Quarterly Yearly

3. Financial Health of Amylyx (5 min.)

4. Comparing to competitors in the Biotechnology industry (5 min.)

Industry Rankings (Biotechnology)

Richest
#175 / 1215

Most Revenue
#211 / 1215

Most Profit
#1008 / 1215

Most Efficient
#1061 / 1215

Fundamentals of Amylyx

Financial Health

Profitability Details

	Compared to previous year	Compared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.

Operating Efficiency Details

	Compared to previous year	Compared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.

Liquidity Details

	Compared to previous year	Compared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.

Solvency Details

	Compared to previous year	Compared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Amylyx Pharmaceuticals Inc.

1.1. Profitability

1.1.1. Net Profit Margin

Measures how much net profit Amylyx earns for each $1 of revenue.

Above 10% is considered healthy but always compare Amylyx to the Biotechnology industry mean.
A Net Profit Margin of 2.2% means that $0.02 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Amylyx Pharmaceuticals Inc:

The MRQ is 2.2%. The company is making a profit. +1
The TTM is -3,943.6%. The company is making a huge loss. -2

Trends

Current period		Compared to		+/-
MRQ	2.2%	TTM	-3,943.6%	+3,945.8%
TTM	-3,943.6%	YOY	-	-3,943.6%
TTM	-3,943.6%	5Y	-1,577.4%	-2,366.2%
5Y	-1,577.4%	10Y	-1,577.4%	0.0%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	2.2%	-193.4%	+195.6%
TTM	-3,943.6%	-273.6%	-3,670.0%
YOY	-	-315.2%	+315.2%
5Y	-1,577.4%	-539.0%	-1,038.4%
10Y	-1,577.4%	-664.9%	-912.5%

Measures how much net profit Amylyx earns for each $1 of revenue.

Revenue is the amount of profit Amylyx generates before taxes and all other costs. For example, when you buy a cup of coffee it will cost you $3. The company does not earn $3 in profit but also has to pay various costs and taxes to create that cup of coffee. Let's assume the cost of creating a cup of coffee is $1.5.

The $3 you pay for a cup of coffee is called revenue.
The $1.5 that’s left over when all costs to create that cup of coffee (including taxes) are deduced from the revenue is called net profit.

The net profit margin looks at how much net profit Amylyx earns for each $1 in revenue.

How to use net profit margin

Higher profit margin is better (more profit).
Above 10% is considered healthy but always compare Amylyx to the Biotechnology industry mean.
Can be used to compare companies within the Biotechnology industry.

You typically want a high profit margin. This means that for each $1 in sales, Amylyx makes more profit. This shows the investor how efficiently Amylyx is operating in general and compared to other companies in the same industry. Amylyx operates in the Biotechnology industry.

Why do investors use net profit margin in their analysis

It helps investors to determine the efficiency of Amylyx. If profit margins remain low (compared to the Biotechnology industry mean) and there are no improvements to make in production costs or other areas that might be a warning sign. If profit margins are high that means the company has low overhead costs and is efficiently using its resources to generate profit.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Net Profit Margin of Amylyx is 0.02. This means that Amylyx earned $0.02 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Net Profit Margin of the Biotechnology industry is -193.4%.
What is the trend?
The trend is important because it shows you how Amylyx is performing over time. The most recent quarter might be important if Amylyx released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Amylyx up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare Amylyx with other companies in the same industry (Biotechnology).
Net profit margin should rise over the years.
Can be influenced when Amylyx sells assets (profit will increase while costs remain the same).
It won’t show what part of Amylyx is doing great or needs improvement (it only looks at total revenue and total net income).

How to calculate net profit margin

Net profit margin = net income / total revenue * 100%

Real example of Amylyx

You need the following data to determine net profit margin:

Income statement from the period you want to calculate (for example, MRQ or TTM).

Net income MRQ Amylyx = 1,573
Total revenue MRQ Amylyx = 71,428
$1,573 / $71,428 = 0.02 or 2.2%

Higher is better

The higher the net profit margin, the more efficient the company is generating income. This helps investors to determine how the company is managing money. The net profit margin is an important indicator when diving into the financial health of a company. Overall, you want to see the net profit margin rising over the years. That means the company improved their production and made it more efficient (if possible).

You can use the net profit margin to compare companies within the same industry. If there are two companies where one is much bigger but the smaller one has a higher net profit margin, that means the smaller company is more efficiently using operational costs.

Important: Profit margins can be very different between industries. Companies with assembly lines or transports are much more prone to see shifting in prices for fuel, ingredients and maintenance compared to companies that only provide services. You should never compare net profit margin between different industries.

1.1.2. Return on Assets

Shows how efficient Amylyx is using its assets to generate profit.

Above 5% is considered healthy but always compare Amylyx to the Biotechnology industry mean.
0.4% Return on Assets means that Amylyx generated $0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Amylyx Pharmaceuticals Inc:

The MRQ is 0.4%. Using its assets, the company is inefficient in making profit. -1
The TTM is -16.0%. Using its assets, the company is very inefficient in making profit. -2

Trends

Current period		Compared to		+/-
MRQ	0.4%	TTM	-16.0%	+16.4%
TTM	-16.0%	YOY	-74.4%	+58.4%
TTM	-16.0%	5Y	-53.7%	+37.7%
5Y	-53.7%	10Y	-53.7%	0.0%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.4%	-12.3%	+12.7%
TTM	-16.0%	-12.4%	-3.6%
YOY	-74.4%	-10.9%	-63.5%
5Y	-53.7%	-15.3%	-38.4%
10Y	-53.7%	-17.6%	-36.1%

Shows how efficient Amylyx is using its assets to generate profit.

For a farm, a tractor is considered an asset. The tractor helps ploughing the land making it possible to plant and harvest crops. But the tractor might be old and needing maintenance all the time reducing its efficiency. Return on assets indicates how effectively the farm is using the tractor (and other assets that help the core business) to plough the land.

How to use return on assets

Higher is better.
Above 5% is considered healthy but always compare Amylyx to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on assets in their analysis

Shows the investor how effectively Amylyx is using its resources to generate profit. If the return on assets (0.4%) from Amylyx are higher than the Biotechnology mean (-12.3%) that means Amylyx is using its resources better than their competitors. If not, that means their competitors are more efficient in using their resources to generate profit.

An investor should always look at:

What is the current return on assets?
The current most recent quarter (MRQ) Return on Assets of Amylyx is 0.4%. This means the company generated $0.00 for each $1 in assets.
How does it compare to the industry?
The mean MRQ Return on Assets of the Biotechnology industry is -12.3%.
What is the trend?
The trend is important because it shows you how Amylyx is performing over time. The most recent quarter might be important if Amylyx released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Amylyx up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
If a company has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

How to calculate return on assets

Return on assets = net income / total assets * 100%

Real example Amylyx

You need the following data to determine return on assets (ROA):

Income statement
Balance sheet

Net income MRQ (income statement) from Amylyx = 1,573
Total assets MRQ (balance sheet) from Amylyx = 407,958
1,573 / 407,958 = 0.00 or 0.4%

ROA is an important ratio as it will tell you how effectively Amylyx is using its resources to generate profits. Example:

Bob and Kristin both sell ice cream in the summer. They both have an ice cream truck. The truck Bob owes cost him $20.000 and the truck Kristin owes cost her $1500. Over the summer, Bob earned $2000 and Kristin earned $200. To calculate the return on assets:

Bob: $2000 / $20.000 * 100% = 10%
Kristin: $200 / $1500 * 100% = 13.3%

This tells you Bob’s company is more valuable but Kristin's company is more efficient. Be aware that total assets can change over time. A transportation business will buy and sell trucks or planes all the time. Before using return on assets as a guideline, you have to know what the exact assets are. For a company that has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

1.1.3. Return on Equity

Shows how efficient Amylyx is using its investors money to generate profit.

Above 15%-20% is considered healthy but always compare Amylyx to the Biotechnology industry mean.
0.4% Return on Equity means Amylyx generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Amylyx Pharmaceuticals Inc:

The MRQ is 0.4%. Using its investors money, the company is inefficient in making profit. -1
The TTM is -19.4%. Using its investors money, the company is very inefficient in making profit. -2

Trends

Current period		Compared to		+/-
MRQ	0.4%	TTM	-19.4%	+19.8%
TTM	-19.4%	YOY	-5.0%	-14.4%
TTM	-19.4%	5Y	-9.7%	-9.6%
5Y	-9.7%	10Y	-9.7%	0.0%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.4%	-15.2%	+15.6%
TTM	-19.4%	-15.5%	-3.9%
YOY	-5.0%	-13.1%	+8.1%
5Y	-9.7%	-20.4%	+10.7%
10Y	-9.7%	-20.9%	+11.2%

Shows how efficient Amylyx is using its investors money to generate profit.

A publicly traded company (any company that issues shares to the public) is owned by its shareholders. Return on equity calculates the amount of profit for every $1 the shareholders invested.

How to use return on equity

Higher is better.
Above 15%-20% is considered healthy but always compare Amylyx to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on equity in their analysis

To find out the owners/management's attitude toward their company. You typically want the owners/management to invest in the company and focus on generating profit. If not enough profit is generated (compared to the Biotechnology industry mean), the company might not be investing their money efficiently.

The three steps every investor should look at:

What is the current return on equity?
The current most recent quarter (MRQ) Return on Equity of Amylyx is 0.4%. This means Amylyx generated $0.00 for each $1 the owners (shareholders) invested.
How does it compare to the industry?
The mean MRQ Return on Equity of the Biotechnology industry is -15.2%.
What is the trend?
The trend is important because it shows you how Amylyx is performing over time. The most recent quarter might be important if Amylyx released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Amylyx up to 10 years back (depending if Amylyx existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Does not include intangible assets (non physical assets like licences, computer software, etc.).
Stockholders equity and shareholders equity refer to the same thing.
Liabilities should not be more than three times return on equity.

How to calculate return on equity

Return on equity = net profit / shareholders equity * 100%

Real example of Amylyx

You need the following data to determine ROE:

Income statement
Balance sheet
Net profit MRQ (income statement) Amylyx = 1,573
Shareholders equity (balance sheet) MRQ Amylyx = 352,648
1,573 / 352,648 = 0.00 or 0.4%

A negative shareholder equity is a warning sign. It means the company has more liabilities than assets. It might also mean that the owners did not invest enough money or they are taking money out of the business.

1.2. Operating Efficiency of Amylyx Pharmaceuticals Inc.

1.2. Operating Efficiency

1.2.1. Operating Margin

Measures how efficient Amylyx is operating .

Measures how much profit Amylyx makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
Above 15% is considered healthy but always compare Amylyx to the Biotechnology industry mean.
An Operating Margin of 2.0% means the company generated $0.02 for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Amylyx Pharmaceuticals Inc:

The MRQ is 2.0%. The company is operating less efficient.
The TTM is -4,012.8%. The company is operating very inefficient. -2

Trends

Current period		Compared to		+/-
MRQ	2.0%	TTM	-4,012.8%	+4,014.8%
TTM	-4,012.8%	YOY	-	-4,012.8%
TTM	-4,012.8%	5Y	-1,605.1%	-2,407.7%
5Y	-1,605.1%	10Y	-1,605.1%	0.0%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	2.0%	-316.7%	+318.7%
TTM	-4,012.8%	-267.4%	-3,745.4%
YOY	-	-333.8%	+333.8%
5Y	-1,605.1%	-517.0%	-1,088.1%
10Y	-1,605.1%	-624.7%	-980.4%

Measures how efficient Amylyx is operating .

The more effecient a company creates products or provides services, the more profit it generates.

How to use operating margin

Higher is better
Above 15% is considered healthy but always compare Amylyx to the Biotechnology industry mean.
Can be very different between industries
Can be used to compare companies

Why do investors use operating margin in their analysis

To determine how much profit Amylyx is making from it’s core business.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Operating Margin of Amylyx is 2.0%. This means that Amylyx earned $0.02 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Margin of the Biotechnology industry is -316.7%.
What is the trend?
The trend is important because it shows you how Amylyx is performing over time. The most recent quarter might be important if Amylyx released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Amylyx up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Can be calculated in different ways

How to calculate operating margin

Operating margin = operating earnings / total revenue

Real example of Amylyx

You need the following data to determine operating margin:

Income statement
Operating earnings MRQ Amylyx = -2,053
Total revenue MRQ Amylyx = 71,428
$-2,053 / $71,428 = 0.02 or 2.0%

Operating margin is used to calculate how much profit a company makes after variable costs of production but before paying interest and taxes. Some variable costs examples are wages, raw materials, packaging, and transaction fees. The amount of variable costs is different for each company and industry. In general, a higher operating margin is better as this implicates that a company is running efficiently.

For investors, a higher operating margin is a good sign. Although you should always look at operating margin in the long term. If operating margin is fluctuating over the years this might be a sign that things are not running efficiently enough. It’s a way to check how much profit a company is making from its core business.

Operation earnings can be calculated in multiple ways:

Operation earnings = EBIT - non operating income + non operating expense
Operation earnings = Gross profit - operating expense - depreciation and amortisation
Operation earnings = Total revenue - COGS (costs of goods sold) - indirect costs

1.2.2. Operating Ratio

Measures how efficient Amylyx is keeping operating costs low.

Below 1 is considered healthy (always compare to Biotechnology industry mean).
An Operation Ratio of 1.03 means that the operating costs are $1.03 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Amylyx Pharmaceuticals Inc:

The MRQ is 1.029. The company is inefficient in keeping operating costs low. -1
The TTM is 40.891. The company is inefficient in keeping operating costs low. -1

Trends

Current period		Compared to		+/-
MRQ	1.029	TTM	40.891	-39.862
TTM	40.891	YOY	-	+40.891
TTM	40.891	5Y	16.356	+24.534
5Y	16.356	10Y	16.356	0.000

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	1.029	2.989	-1.960
TTM	40.891	3.644	+37.247
YOY	-	4.537	-4.537
5Y	16.356	6.411	+9.945
10Y	16.356	8.312	+8.044

Measures how efficient Amylyx is keeping operating costs low.

If the operating ratio is below 1 that means the company is making money. The lower the operating ratio, the more efficient the company.

How to use operating ratio

Lower is better.
Below 1 is considered healthy but always compare Amylyx to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use operating ratio in their analysis

Shows if costs of creating products and or services is increasing or decreasing. The lower the operating ratio, the more efficient the company is creating products and services.

The three steps every investor should look at:

What is the current Operatin ratio?
The current most recent quarter (MRQ) Operating Ratio of Amylyx is 102.9%. This means that Amylyx earned $1.03 for each $1 in net sales in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Ratio of the Biotechnology industry is 2.99.
What is the trend?
The trend is important because it shows you how Amylyx is performing over time. The most recent quarter might be important if Amylyx released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Amylyx up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
You need COGS to calculate operating ratio which is not always shown in the income statement.
Does not consider debt.

How to calculate operating ratio

Operating ratio = Operating expenses + COGS \ Net sales

Real life example Amylyx

You need the following data to determine operating ratio:

Income statement

COGS is not always specified on the income statement. If so you can use the following calculation:

(cost of revenue + total operating expenses) \ total revenue
(5,283 +68,198) \ 71,428 = 1.03

The operating ratio measures the efficiency of a company at keeping low costs while generating profits from sales. It compares the total operating expenses to the net amount of sales. The total operating expenses exists of:

COGS (materials, labour, rent of facility, repairs)
Operating expenses (legal fees, marketing, wages, rent, maintenance/repairs)

Operating expenses are all the costs the company makes that are not directly tied to the production of the service or product. Where COGS are costs that are directly tied to the production of a product or service.

Do note that COGS is not always available in the income statement. Some companies include COGS in the operating expenses while others list COGS separately. To make it even more confusing, COGS is also known as “costs of sales” and costs of sales is the same as costs of revenue.

The operating ratio tells you how efficient the company is creating its products or services while keeping prices low. In this case, a lower ratio is better. Higher or rising operating ratios might tell you that costs are rising while sales are not improving or staying the same.

1.3. Liquidity of Amylyx Pharmaceuticals Inc.

1.3. Liquidity

1.3.1. Current Ratio

Measures if Amylyx is able to pay off Short-term Debt.

Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
A Current Ratio of 8.06 means the company has $8.06 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Amylyx Pharmaceuticals Inc:

The MRQ is 8.059. The company is very able to pay all its short-term debts. +2
The TTM is 7.372. The company is very able to pay all its short-term debts. +2

Trends

Current period		Compared to		+/-
MRQ	8.059	TTM	7.372	+0.687
TTM	7.372	YOY	6.049	+1.324
TTM	7.372	5Y	5.555	+1.818
5Y	5.555	10Y	5.555	0.000

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	8.059	4.559	+3.500
TTM	7.372	4.993	+2.379
YOY	6.049	6.149	-0.100
5Y	5.555	6.306	-0.751
10Y	5.555	6.588	-1.033

Measures if Amylyx is able to pay off Short-term Debt.

How to use current ratio

Higher is better
Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
Can be very different between industries
Can be used to compare companies

Why do investors use current ratio in their analysis

Shows if the company can pay of short term debts if needed. A company that can't pay off it's short term debts might get in trouble if they have to pay off their short term debts for whatever reason. For example, markets can change due to global events like covid-19 or the war in Ukraine versus Russia. Because debts are always taken based on future income, it might become troublesome for Amylyx if something happens in the market that will cause sales to plummet.

The three steps every investor should look at:

What is the current current Ratio?
The current most recent quarter (MRQ) Current Ratio of Amylyx is 8.06. This means Amylyx has $8.06 in assets for each $1 in short-term debts.
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 4.56.
What is the trend?
The trend is important because it shows you how Amylyx is performing over time. The most recent quarter might be important if Amylyx released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Amylyx up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Might be deluded.
Not all assets can always be quickly sold.
Can be manipulated by increasing or decreasing the assets and/or liabilities.

How to calculate current ratio

Current ratio = current assets \ current liabilities

Real life example Amylyx

You need the following data to determine operating ratio:

Balance sheet
Current ratio = current assets \ current liabilities
399,126 \ 49,523) = 8.06

The current ratio measures if Amylyx is able to pay short-term debts (obligations). Short term in this context means all debt obligations that are about to expire within one year. The current ratio incorporates current liabilities and current assets. Current assets are all the assets a company has that are expected to be consumed or sold within standard business operations. You can find the current assets in the balance sheet. They consist of:

Inventory
Accounts receivable
Marketable securities
Prepaid expenses
Cash
Cash equivalents
liquid assets

The current liabilities are short term obligations that are due within one year. These consist of:

Short term debts
Dividends
Income taxes
Short-term debts
Accounts payable
Interest payments

The result shows an investor if Amylyx is able to pay all its short-term debts if they were due all at once. When the result of the above formula is below 1, then Amylyx does not have enough capital after selling all its assets to pay all short-term debts. If the ratio drops far below 1 that might indicate Amylyx is or will be in financial trouble anytime soon.

Although this gives an investor some clues, the current ratio may also be deluded. Because owning assets does not mean the company can easily sell them. Also, Accounts receivable may be quite old (they will probably never pay) which deludes the current ratio. As with all ratios, you should only compare them between the same industries and companies.

1.3.2. Quick Ratio

Measures if Amylyx is able to pay off Short-term Debt but only using the most liquid assets.

Above 1 is considered healthy but always compare Amylyx to the Biotechnology industry mean.
A Quick Ratio of 12.00 means the company can pay off $12.00 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Amylyx Pharmaceuticals Inc:

The MRQ is 12.001. The company is very able to pay all its short-term debts with the most liquid assets. +2
The TTM is 11.319. The company is very able to pay all its short-term debts with the most liquid assets. +2

Trends

Current period		Compared to		+/-
MRQ	12.001	TTM	11.319	+0.683
TTM	11.319	YOY	8.535	+2.784
TTM	11.319	5Y	8.117	+3.202
5Y	8.117	10Y	8.117	0.000

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	12.001	3.874	+8.127
TTM	11.319	4.499	+6.820
YOY	8.535	5.772	+2.763
5Y	8.117	5.816	+2.301
10Y	8.117	6.032	+2.085

1.4. Solvency of Amylyx Pharmaceuticals Inc.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Measures how much % of Amylyx assets are financed with debt.

Below 1 (100%) is considered healthy but always compare Amylyx to Biotechnology industry mean.
A Debt to Asset Ratio of 0.14 means that Amylyx assets are financed with 13.6% credit (debt) and the remaining percentage (100% - 13.6%) is financed by its owners/shareholders.

Let's take a look of the Debt to Asset Ratio trends of Amylyx Pharmaceuticals Inc:

The MRQ is 0.136. The company is very able to pay all its debts by selling its assets. +2
The TTM is 0.154. The company is very able to pay all its debts by selling its assets. +2

Trends

Current period		Compared to		+/-
MRQ	0.136	TTM	0.154	-0.018
TTM	0.154	YOY	1.992	-1.838
TTM	0.154	5Y	2.005	-1.851
5Y	2.005	10Y	2.005	0.000

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.136	0.311	-0.175
TTM	0.154	0.298	-0.144
YOY	1.992	0.269	+1.723
5Y	2.005	0.377	+1.628
10Y	2.005	0.409	+1.596

Measures how much % of Amylyx assets are financed with debt.

When there are more debts than assets, that means creditors have a larger stake Amylyx than its shareholders.

How to use debt to asset ratio

Lower is better.
below 1 (100%) is considered healthy but always compare Amylyx to Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to asset ratio in their analysis

It shows how much debt the company used to finance its assets. If a company is almost entirely financed with debt that means the company might get into serious trouble when emergencies arise like a raise in interest.

The three steps every investor should look at:

What is the current debt to asset ratio?
The current most recent quarter (MRQ) Debt to Asset Ratio of Amylyx is 0.14. This means means that Amylyx is financed with 13.6% credit and the remaining percentage is financed by it's owners (shareholders).
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 455.9%.
What is the trend?
The trend is important because it shows you how Amylyx is performing over time. The most recent quarter might be important if Amylyx released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Amylyx up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Some companies can have higher debt to assets ratio's (for example, banks).
Debt to asset ratio should improve over the years.
If the debt to asset ratio is above 1, look at the industry mean and find out why Amylyx has so much debt.

How to calculate debt to asset ratio

Debt to asset ratio = total debt \ total assets

Real life example Amylyx

You need the following data to determine debt to asset ratio:

Balance sheet
Debt to asset ratio = total debt \ total assets
55,310 \ 407,958 = 13.6% or 0.14.

The debt to total assets ratio shows if the company is owned by creditors or shareholders. Or in other words, the total debt in relation to the total amount of assets. It shows how much debt the company used to finance its assets.

1.4.2. Debt to Equity Ratio

Measures if Amylyx is able to pay off its debts by using shareholders equity.

Below 2 is considered healthy but always compare Amylyx to the Biotechnology industry mean.
A Debt to Equity ratio of 15.7% means that company has $0.16 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Amylyx Pharmaceuticals Inc:

The MRQ is 0.157. The company is very able to pay all its debts with equity. +2
The TTM is 0.184. The company is very able to pay all its debts with equity. +2

Trends

Current period		Compared to		+/-
MRQ	0.157	TTM	0.184	-0.027
TTM	0.184	YOY	0.035	+0.149
TTM	0.184	5Y	0.087	+0.096
5Y	0.087	10Y	0.087	0.000

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.157	0.363	-0.206
TTM	0.184	0.362	-0.178
YOY	0.035	0.277	-0.242
5Y	0.087	0.425	-0.338
10Y	0.087	0.463	-0.376

Measures if Amylyx is able to pay off its debts by using shareholders equity.

How to use debt to equity ratio

Lower is better.
Below 2 is considered healthy (always use industry average).
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to shareholders equity ratio in their analysis

It shows how much debt the company uses to finance their operations. Shareholders equity is whats left over when you subtract total liabilities from total assets. It's another way to meassure how much of Amylyx is financed with debt or own resources.

The three steps every investor should look at:

What is the current debt to equity ratio?
The current most recent quarter (MRQ) quickRatio of Amylyx is 0.16. This means that Amylyx can pay off $0.16 for each $1 in debt.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is 0.36.
What is the trend?
The trend is important because it shows you how Amylyx is performing over time. The most recent quarter might be important if Amylyx released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Amylyx up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Not all debt is equally risky (for example, short term risk is less risky).

How to calculate debt to equity ratio

Debt to equity ratio = total debt \ shareholders equity.

Real life example Amylyx

You need the following data to determine equity ratio:

Balance sheet
Debt to equity ratio = total debt \ shareholders equity
55,310 \ 352,648 = 0.16 or 15.7%

Debt to equity measures the total debt versus the total shareholders equity. While the total debts to total assets ratio uses total assets, the debt to equity ratio looks at the total equity of shareholders. Where equity of shareholders are:

Common shares.
Preferred shares.
Retained earnings.

You can find the shareholders' equity in the balance sheet. A ratio between 0,5 and 1,5 is preferred. If the ratio is above 1.5, that would indicate creditors have significantly more stake (debt) in the company than the shareholders. In other words, the company is using a lot of debt to finance their operations.

Not all debt is equally risky. Meaning you can adjust the ratio by including or excluding certain amounts of debt. Short term debts are less risky because they have to be paid back within one year anyway. It’s much easier to plan one year ahead versus five or ten years.

2. Market Valuation of Amylyx Pharmaceuticals Inc

2. Earnings Per Share

2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Amylyx generates.

Above 15 is considered overpriced but always compare Amylyx to the Biotechnology industry mean.
A PE ratio of 1,321.77 means the investor is paying $1,321.77 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Amylyx Pharmaceuticals Inc:

The EOD is 1,151.478. Seems overpriced? -1
The MRQ is 1,321.767. Seems overpriced? -1
The TTM is 301.134. Seems overpriced? -1

Trends

Current period		Compared to		+/-
EOD	1,151.478	MRQ	1,321.767	-170.289
MRQ	1,321.767	TTM	301.134	+1,020.633
TTM	301.134	YOY	-4.510	+305.644
TTM	301.134	5Y	118.649	+182.484
5Y	118.649	10Y	118.649	0.000

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	1,151.478	-6.478	+1,157.956
MRQ	1,321.767	-7.165	+1,328.932
TTM	301.134	-8.420	+309.554
YOY	-4.510	-19.867	+15.357
5Y	118.649	-18.328	+136.977
10Y	118.649	-18.055	+136.704

Measures how much money you pay for each share for every $1 in earnings Amylyx generates.

Indicates if the company’s shares are under or overvalued.

How to use PE ratio

Above 15 is considered overpriced but is hard to determine. Always compare Amylyx to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use PE ratio in their analysis

The PE ratio tells investors the current sentiment in the market for that company. As with every stock, the stock price never shows the real valuation of a company but rather how the market thinks how much the stock is worth.

In other words, the current stock price also incorporates any future earnings or business opportunities in the future. The best example is the stock market crash in 2000. The PE ratio for any internet based company was going through the roof. Only based on the general assumption the internet and all associated businesses would thrive in the future. But this was based on nothing. A business still needs a good product or service to be able to survive. Instead, every investor bought any stock which did something related to the internet. Result: huge market crash.

Many investors were willing to pay premium prices and that was causing the PE ratio to rise. A high PE ratio is a warning sign that investors might be overvaluing a stock based on future earnings.

The three steps every investor should look at:

What is the current PE Ratio?
The current most recent quarter (MRQ) PE Ratio of Amylyx is 1,321.77. This means the investor is paying $1,321.77 for every $1 in earnings.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is -7.17.
What is the trend?
The trend is important because it shows you how Amylyx is performing over time. The most recent quarter might be important if Amylyx released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Amylyx up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Some industries might have very high or very low PE ratios in general.
PE ratios can be high for several years, it does not mean a sudden collapse is imminent.
Earnings growth is not included in the PE ratio.

How to calculate PE ratio

PE ratio = market value per share \ earnings per share

Real life example Amylyx

You need the following data to determine the PE ratio:

Balance sheet
Income statement

The PE ratio is a very commonly used ratio to determine the value of a company by comparing the current stock price relative to its earnings per share (EPS). Before we can calculate the PE ratio we need to know the EPS. EPS is calculated as follows:

EPS = (net profit - preferred dividends) \ end of period outstanding shares*
Net profit = revenue - expenses
1,573 \ 70,864 = EPS
PE ratio MRQ = 1,321.77

* The net profit minus preferred dividends can be found in the incomestatement as netIncomeApplicableToCommonShares.

The PE value helps investors to determine if the current stock price is under or overvalued. It also projects future growth.

In general, a higher PE ratio means that investors predict higher future growth. If the PE ratio is too high, then investors expect way too much future growth the company can never fulfil. This is most likely to happen in faster moving companies like tech companies or automobile companies like Tesla. These are hot and booming markets where investors expect much future growth driven by new technology (electric cars). When looking at the current MRQ (most recent quarter) PE ratio of Tesla ( jan. 2021) it's about 247 while the average in the industry is only 6. That might be a clue that Tesla is trading for way too high prices compared to their current assets and is more based on future growth.

2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Amylyx.

Lower is better.
A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Amylyx Pharmaceuticals Inc:

The MRQ is 649.543. Seems overpriced? -1
The TTM is 134.712. Seems overpriced? -1

Trends

Current period		Compared to		+/-
MRQ	649.543	TTM	134.712	+514.831
TTM	134.712	YOY	-57.845	+192.557
TTM	134.712	5Y	96.201	+38.511
5Y	96.201	10Y	96.201	0.000

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	649.543	-4.292	+653.835
TTM	134.712	-6.108	+140.820
YOY	-57.845	-13.925	-43.920
5Y	96.201	-12.525	+108.726
10Y	96.201	-11.713	+107.914

PEG Ratio	Meaning
0.5	You can buy the stock cheap based on future growth
1	You pay a fair price based on future growth
2	The stock is overpriced based on future growth

2. Book Value per Share

2.3. Price to Book Ratio

Measures if the stock price of Amylyx is to cheap or to expensive compared to its book value.

At or below 1 is considered healthy (always compare to Biotechnology industry mean).
A PB ratio of 5.90 means the investor is paying $5.90 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Amylyx Pharmaceuticals Inc:

The EOD is 5.136. Seems overpriced? -1
The MRQ is 5.896. Seems overpriced? -1
The TTM is 8.256. Seems overpriced? -1

Trends

Current period		Compared to		+/-
EOD	5.136	MRQ	5.896	-0.760
MRQ	5.896	TTM	8.256	-2.360
TTM	8.256	YOY	0.896	+7.360
TTM	8.256	5Y	3.661	+4.595
5Y	3.661	10Y	3.661	0.000

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	5.136	1.890	+3.246
MRQ	5.896	2.024	+3.872
TTM	8.256	2.335	+5.921
YOY	0.896	3.965	-3.069
5Y	3.661	3.738	-0.077
10Y	3.661	4.002	-0.341

2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Amylyx Pharmaceuticals Inc.

3.1. Institutions holding Amylyx Pharmaceuticals Inc

Institutions are holding 81.986% of the shares of Amylyx Pharmaceuticals Inc.

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2022-12-31	Perceptive Advisors LLC	9.0716	6.3171	6088333	616300	11.2627
2023-03-31	Vanguard Group Inc	7.0736	0.0036	4747341	388849	8.9216
2022-12-31	Viking Global Investors LP	6.9056	0.8573	4634606	-1135930	-19.685
2022-12-31	BlackRock Inc	5.3892	0.0042	3616926	1321092	57.543
2022-12-31	Deerfield Management Co	4.0126	2.0597	2693000	2693000	0
2022-12-31	Point72 Asset Management, L.P.	3.1707	0.2673	2127960	1660999	355.704
2022-12-31	Boxer Capital LLC	3.1052	4.0594	2084000	0	0
2023-03-31	D. E. Shaw & Co LP	3.0133	0.0635	2022370	638638	46.1533
2022-12-31	Federated Hermes Inc	2.4061	0.165	1614845	285845	21.5083
2022-12-31	Rock Springs Capital Management LP	1.8322	1.0933	1229637	825900	204.5639
2023-03-31	State Street Corporation	1.5887	0.0018	1066238	-9374	-0.8715
2022-12-31	Goldman Sachs Group Inc	1.544	0.0086	1036270	656871	173.1346
2023-03-31	Adage Capital Partners Gp LLC	1.5009	0.0663	1007336	-901865	-47.2378
2023-03-31	Emerald Advisers, LLC	1.4495	1.3688	972835	135926	16.2414
2022-12-31	Millennium Management LLC	1.2805	0.0176	859415	-61713	-6.6997
2022-12-31	Geode Capital Management, LLC	1.2723	0.0044	853913	218357	34.3568
2022-12-31	Falcon Edge Capital LP	1.2236	5.5414	821220	120585	17.2108
2023-03-31	Emerald Mutual Fund Advisers Trust	1.1765	1.3685	789591	134576	20.5455
2022-12-31	Balyasny Asset Management LLC	0.9619	0.0653	645553	454219	237.3959
2022-12-31	Nuveen Asset Management, LLC	0.8881	0.0085	596054	239367	67.1084
Total		58.8661	23.3416	39507443	+8281642	+21.0%

3.2. Funds holding Amylyx Pharmaceuticals Inc

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2023-04-30	Vanguard Total Stock Mkt Idx Inv	2.4655	0.0037	1654702	795	0.0481
2023-03-31	Vanguard Instl Ttl Stck Mkt Idx Tr	2.4643	0.0039	1653907	147574	9.7969
2023-04-30	Vanguard Small Cap Index	2.0676	0.0336	1387659	-342	-0.0246
2023-04-28	iShares Russell 2000 ETF	1.6118	0.0631	1081711	-12480	-1.1406
2023-04-30	Vanguard Small Cap Growth Index Inv	1.1859	0.0781	795921	3150	0.3973
2023-03-31	Federated Hermes Kaufmann Growth	1.1542	0.4749	774637	0	0
2023-03-31	Federated Hermes Kaufmann R	1.1542	0.4752	774637	0	0
2023-03-31	Federated Hermes Kaufmann Small Cap Grow	1.0899	0.4978	731462	0	0
2023-03-31	Federated Hermes Kaufmann Small Cap A	1.0899	0.4982	731462	0	0
2023-01-31	Biotech Growth Ord	0.9148	4.6461	613959	613959	0
2023-04-30	Vanguard Extended Market Index Investor	0.8107	0.0185	544072	413	0.076
2023-02-28	Fidelity® Small Cap Index	0.6296	0.0713	422558	6549	1.5742
2023-03-31	Emerald Growth A	0.6271	1.3796	420874	68177	19.3302
2023-04-28	iShares Russell 2000 Value ETF	0.6119	0.1068	410638	753	0.1837
2023-03-31	CREF Stock R1	0.5057	0.009	339413	0	0
2023-04-30	Voya MidCap Opportunities Port I	0.4896	0.9413	328586	120477	57.8913
2023-04-28	iShares Biotechnology ETF	0.4613	0.1115	309620	-1792	-0.5754
2023-04-30	Principal SmallCap Growth I Instl	0.3975	0.3332	266763	-64	-0.024
2022-10-31	Pictet-Biotech P USD	0.3896	0.559	261444	261444	0
2023-04-30	State St Russell Sm/Mid Cp® Indx NL Cl C	0.3812	0.0231	255849	0	0
Total		20.5023	10.3279	13759874	+1208613	+8.8%

3.3. Insider Transactions

Insiders are holding 23.461% of the shares of Amylyx Pharmaceuticals Inc.

Date	Owner	Type	Amount	Price	Post Transaction Amount
2023-05-16	James M Frates	SELL	32500	26.94	55676
2023-05-15	Patrick D Yeramian	SELL	11965	29.03	208417
2023-04-17	Patrick D Yeramian	SELL	49579	30.54	208417
2023-03-29	Morningside Venture Investment	SELL	29048	30.45	6997302
2023-03-27	Morningside Venture Investment	SELL	60964	30.5	7126350
2023-03-21	Morningside Venture Investment	SELL	63448	31.91	7187314
2023-03-16	George M Milne Jr	SELL	35000	31.89	862021
2023-03-16	James M Frates	SELL	32500	31.89	1509
2023-03-16	Justin B Klee	SELL	100000	31.86	2792617
2023-03-16	Morningside Venture Investment	SELL	9122	32.55	7250762
2023-03-16	Patrick D Yeramian	SELL	54627	31.87	149672
2023-03-14	Morningside Venture Investment	SELL	70714	34.54	7409884
2023-03-02	Morningside Venture Investment	SELL	50000	33.75	7480598
2023-02-24	Gina Mazzariello	SELL	3586	34.49	37414
2023-02-22	Morningside Venture Investment	SELL	50000	34.73	7530598
2022-09-08	Global Investors Lp Viking	SELL	700000	29.37	2075470

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Amylyx Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

	End of day	+/-	Most Recent Quarter	Trailing 12 Months	+/-	Year-Over-Year	+/-	5 Year	+/-	10 Year	+/-
Book Value Change Per Share	-	-	-0.094	0.347	-127%	1.145	-108%	0.498	-119%	0.498	-119%
Book Value Growth	-	-	1.035	1.237	-16%	1.646	-37%	1.392	-26%	1.392	-26%
Book Value Per Share	-	-	4.976	3.765	+32%	0.515	+867%	1.513	+229%	1.513	+229%
Book Value Per Share Growth	-	-	0.981	1.223	-20%	1.646	-40%	1.386	-29%	1.386	-29%
Current Ratio	-	-	8.059	7.372	+9%	6.049	+33%	5.555	+45%	5.555	+45%
Debt To Asset Ratio	-	-	0.136	0.154	-12%	1.992	-93%	2.005	-93%	2.005	-93%
Debt To Equity Ratio	-	-	0.157	0.184	-15%	0.035	+351%	0.087	+80%	0.087	+80%
Dividend Per Share	-	-	-	-	0%	-	0%	-	0%	-	0%
Eps	-	-	0.022	-0.555	+2599%	-0.452	+2137%	-0.437	+2069%	-0.437	+2069%
Eps Growth	-	-	2.035	1.279	+59%	0.312	+552%	1.086	+87%	1.086	+87%
Free Cash Flow Per Share	-	-	-0.075	-0.545	+626%	-0.385	+413%	-0.404	+438%	-0.404	+438%
Free Cash Flow Per Share Growth	-	-	1.900	1.167	+63%	0.641	+196%	0.870	+118%	0.870	+118%
Free Cash Flow To Equity Per Share	-	-	-0.060	1.062	-106%	0.854	-107%	0.775	-108%	0.775	-108%
Free Cash Flow To Equity Per Share Growth	-	-	-0.022	1.516	-101%	4.579	-100%	3.119	-101%	3.119	-101%
Gross Profit Margin	-	-	1.000	1.091	-8%	1.000	0%	1.036	-4%	1.036	-4%
Intrinsic Value_10Y_max	-	-	-79.212	-	-	-	-	-	-	-	-
Intrinsic Value_10Y_min	-	-	-66.537	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_max	-	-	-3.018	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_min	-	-	-2.961	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_max	-	-	-12.817	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_min	-	-	-12.160	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_max	-	-	-27.136	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_min	-	-	-24.865	-	-	-	-	-	-	-	-
Net Profit Margin	-	-	0.022	-39.436	+179174%	-	+100%	-15.774	+71730%	-15.774	+71730%
Operating Margin	-	-	0.020	-40.128	+204397%	-	+100%	-16.051	+81819%	-16.051	+81819%
Operating Ratio	-	-	1.029	40.891	-97%	-	+100%	16.356	-94%	16.356	-94%
Pb Ratio	5.136	-15%	5.896	8.256	-29%	0.896	+558%	3.661	+61%	3.661	+61%
Pe Ratio	1151.478	-15%	1321.767	301.134	+339%	-4.510	+100%	118.649	+1014%	118.649	+1014%
Peg Ratio	-	-	649.543	134.712	+382%	-57.845	+109%	96.201	+575%	96.201	+575%
Price Per Share	25.560	-15%	29.340	28.425	+3%	3.213	+813%	12.655	+132%	12.655	+132%
Price To Total Gains Ratio	-272.114	+13%	-312.357	-91.344	-71%	5.651	-5628%	-71.945	-77%	-71.945	-77%
Profit Growth	-	-	2.037	1.280	+59%	0.302	+575%	0.716	+185%	0.716	+185%
Quick Ratio	-	-	12.001	11.319	+6%	8.535	+41%	8.117	+48%	8.117	+48%
Return On Assets	-	-	0.004	-0.160	+4260%	-0.744	+19398%	-0.537	+14038%	-0.537	+14038%
Return On Equity	-	-	0.004	-0.194	+4441%	-0.050	+1213%	-0.097	+2282%	-0.097	+2282%
Revenue Growth	-	-	3.264	33.349	-90%	-	-	33.349	-90%	33.349	-90%
Total Gains Per Share	-	-	-0.094	0.347	-127%	1.145	-108%	0.498	-119%	0.498	-119%
Total Gains Per Share Growth	-	-	-0.032	1.668	-102%	3.211	-101%	2.156	-101%	2.156	-101%
Usd Book Value	-	-	352648000.000	257518000.000	+37%	34583500.000	+920%	103495600.000	+241%	103495600.000	+241%
Usd Book Value Change Per Share	-	-	-0.094	0.347	-127%	1.145	-108%	0.498	-119%	0.498	-119%
Usd Book Value Per Share	-	-	4.976	3.765	+32%	0.515	+867%	1.513	+229%	1.513	+229%
Usd Dividend Per Share	-	-	-	-	0%	-	0%	-	0%	-	0%
Usd Eps	-	-	0.022	-0.555	+2599%	-0.452	+2137%	-0.437	+2069%	-0.437	+2069%
Usd Free Cash Flow	-	-	-5322000.000	-36685750.000	+589%	-25867750.000	+386%	-27191000.000	+411%	-27191000.000	+411%
Usd Free Cash Flow Per Share	-	-	-0.075	-0.545	+626%	-0.385	+413%	-0.404	+438%	-0.404	+438%
Usd Free Cash Flow To Equity Per Share	-	-	-0.060	1.062	-106%	0.854	-107%	0.775	-108%	0.775	-108%
Usd Price Per Share	25.560	-15%	29.340	28.425	+3%	3.213	+813%	12.655	+132%	12.655	+132%
Usd Profit	-	-	1573000.000	-37238500.000	+2467%	-46092000.000	+3030%	-35809000.000	+2376%	-35809000.000	+2376%
Usd Revenue	-	-	71428000.000	23414500.000	+205%	-	+100%	9365800.000	+663%	9365800.000	+663%
Usd Total Gains Per Share	-	-	-0.094	0.347	-127%	1.145	-108%	0.498	-119%	0.498	-119%
	EOD	+4 -1	MRQ	TTM	+24 -16	YOY	+21 -17	5Y	+22 -18	10Y	+22 -18

4.2. Fundamental Score

Let's check the fundamental score of Amylyx Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

Indicator	Condition		Value
Price to Earnings Ratio (EOD)	Between	0-15	1,151.478
Price to Book Ratio (EOD)	Between	0-1	5.136
Net Profit Margin (MRQ)	Greater than	0	0.022
Operating Margin (MRQ)	Greater than	0	0.020
Quick Ratio (MRQ)	Greater than	1	12.001
Current Ratio (MRQ)	Greater than	1	8.059
Debt to Asset Ratio (MRQ)	Less than	1	0.136
Debt to Equity Ratio (MRQ)	Less than	1	0.157
Return on Equity (MRQ)	Greater than	0.15	0.004
Return on Assets (MRQ)	Greater than	0.05	0.004
Total			6/10 (60.0%)

Create your own Stock Scanner

Investing is personal. The best investors buy stocks based on their own analysis. Create your personal Stock Scanner with the key performance indicators that are important to you.
Create your own Stock Scanner

4.3. Technical Score

Let's check the technical score of Amylyx Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Open	Greater than	Close	25.310
Total			0/1 (0.0%)

Create your own Symbol Scanner

Trading is personal. The best traders buy and sell based on their own technical analysis. Create your personal Symbol Scanner with the technical indicators that are important to you.
Create your own Symbol Scanner

Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

	2022-03-31		2022-06-30		2022-09-30		2022-12-31		2023-03-31
Accumulated Other Comprehensive Income	-151	-45	-196	-529	-725	639	-86	111	25
Income before Tax	-47,702	-6,191	-53,893	12	-53,881	11,756	-42,125	43,528	1,403
Net Income	-47,848	-6,219	-54,067	311	-53,756	11,052	-42,704	44,277	1,573
EBIT	-47,814	-6,439	-54,253	-428	-54,681	10,088	-44,593	45,996	1,403
Net Income from Continuing Operations	-47,848	-6,219	-54,067	311	-53,756	11,052	-42,704	44,277	1,573
Net Income Applicable to Common Shares	-47,848	-6,219	-54,067	311	-53,756	11,052	-42,704	44,277	1,573

Latest Balance Sheet

Balance Sheet of 2023-03-31. Currency in USD. All numbers in thousands.

Summary

Total Assets	407,958
Total Liabilities	55,310
Total Stockholder Equity	352,648

	As reported
Total Liabilities	55,310
Total Stockholder Equity	+ 352,648
Total Assets	= 407,958

Assets

Total Assets	407,958
Total Current Assets	399,126
Long-term Assets	399,126

Total Current Assets

Total Current Assets (as reported)	399,126
Cash And Cash Equivalents	114,563
Short-term Investments	231,111
Net Receivables	17,555
Inventory	23,148
Other Current Assets	12,749
Total Current Assets (calculated)	399,126
+/-	0

Long-term Assets

Long-term Assets (as reported)	8,832
Property Plant Equipment	7,647
Long-term Assets Other	1,185
Long-term Assets (calculated)	8,832
+/-	0

Liabilities & Shareholders' Equity

Total Current Liabilities	49,523
Long-term Liabilities	5,787
Total Stockholder Equity	352,648

Total Current Liabilities

Total Current Liabilities (as reported)	49,523
Short-term Debt	2,093
Accounts payable	10,770
Other Current Liabilities	36,660
Total Current Liabilities (calculated)	49,523
+/-	0

Long-term Liabilities

Long-term Liabilities (as reported)	5,787
Capital Lease Obligations	5,787
Long-term Liabilities (calculated)	5,787
+/-	0

Total Stockholder Equity

Total Stockholder Equity (as reported)	352,648
Common Stock	7
Retained Earnings	-352,647
Accumulated Other Comprehensive Income	25
Capital Surplus	705,263
Total Stockholder Equity (calculated)	352,648
+/-	0

Other

Capital Stock	7
Cash and Short Term Investments	345,674
Common Stock Shares Outstanding	70,864
Common Stock Total Equity	7
Liabilities and Stockholders Equity	407,958
Net Debt	-108,776
Net Invested Capital	352,648
Net Tangible Assets	352,648
Net Working Capital	349,603
Short Long Term Debt Total	5,787

Balance Sheet

Currency in USD. All numbers in thousands.

Trend

2023-03-31

2022-12-31

2022-09-30

2022-06-30

2022-03-31

2021-12-31

2021-09-30

2021-06-30

2021-03-31

2020-12-31

> Total Assets

14,104
0
0
130,460
105,614
274,438
225,240
181,443
391,453
407,958

407,958

391,453

181,443

225,240

274,438

105,614

130,460

14,104

> Total Current Assets

13,639
0
0
129,942
104,951
265,488
216,139
172,199
382,133
399,126

399,126

382,133

172,199

216,139

265,488

104,951

129,942

13,639

Cash And Cash Equivalents

12,877
0
0
76,677
50,191
110,403
67,440
107,734
346,945
114,563

114,563

346,945

107,734

67,440

110,403

50,191

76,677

12,877

Short-term Investments

0
0
0
49,025
45,927
144,802
139,241
54,859
284,419
231,111

231,111

284,419

54,859

139,241

144,802

45,927

49,025

Net Receivables

0
0
0
0
0
0
0
137
15,306
17,555

17,555

15,306

137

Other Current Assets

762
0
0
4,240
8,833
10,283
9,458
8,906
10,113
12,749

12,749

10,113

8,906

9,458

10,283

8,833

4,240

762

> Long-term Assets

465
0
0
518
663
8,950
9,101
9,244
9,320
8,832

8,832

9,320

9,244

9,101

8,950

663

518

465

Property Plant Equipment

151
0
0
329
474
8,075
8,226
8,069
8,135
7,647

7,647

8,135

8,069

8,226

8,075

474

329

151

Other Assets

314
0
0
0
189
875
9,101
1,175
0
0

1,175

9,101

875

189

314

> Total Liabilities

80,829
0
0
254,530
17,431
33,492
32,451
37,415
50,846
55,310

55,310

50,846

37,415

32,451

33,492

17,431

254,530

80,829

> Total Current Liabilities

7,326
0
0
15,146
17,396
27,706
27,164
32,647
46,609
49,523

49,523

46,609

32,647

27,164

27,706

17,396

15,146

7,326

Short-term Debt

0
0
0
263
0
1,405
1,787
1,990
2,040
2,093

2,093

2,040

1,990

1,787

1,405

263

Short Long Term Debt

0
0
0
263
0
0
0
0
0
0

263

Accounts payable

3,613
0
0
3,026
4,372
10,045
8,117
7,052
46,609
10,770

10,770

46,609

7,052

8,117

10,045

4,372

3,026

3,613

Other Current Liabilities

3,713
0
0
11,857
13,024
16,256
17,260
23,605
-2,040
36,660

36,660

-2,040

23,605

17,260

16,256

13,024

11,857

3,713

> Long-term Liabilities

73,503
0
0
239,384
35
5,786
5,287
4,768
4,237
5,787

5,787

4,237

4,768

5,287

5,786

239,384

73,503

Long term Debt

1,425
0
0
0
0
0
0
0
0
0

1,425

Capital Lease Obligations Min Short Term Debt

0
0
0
-263
0
5,786
5,287
4,768
4,237
3,694

3,694

4,237

4,768

5,287

5,786

-263

Other Liabilities

16
0
0
0
35
0
7,074
0
0
0

7,074

Long-term Liabilities Other

0
0
0
0
0
5,786
5,287
4,768
4,237
3,694

3,694

4,237

4,768

5,287

5,786

> Total Stockholder Equity

-66,725
0
0
-124,070
-151,168
240,946
192,789
144,028
340,607
352,648

352,648

340,607

144,028

192,789

240,946

-151,168

-124,070

-66,725

Common Stock

1
0
0
1
1
6
6
6
7
7

Retained Earnings

-352,647

-354,220

-311,516

-257,760

-203,693

-155,845

-127,501

-67,914

Capital Surplus

0
0
0
0
0
444,784
450,739
456,263
694,906
705,263

705,263

694,906

456,263

450,739

444,784

Treasury Stock

Other Stockholders Equity

1,188
0
0
3,431
4,667
444,784
225,499
274,820
694,906
297,305

297,305

694,906

274,820

225,499

444,784

4,667

3,431

1,188

Balance Sheet

Currency in USD. All numbers in thousands.

	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Accounts Payable	46,609	17,396	3,613	2,195
Accumulated Other Comprehensive Income	-86	9	-	-
Capital Lease Obligations	6,277	-	-	-
Capital Stock	7	1	1	1
Capital Surpluse	694,906	-	-	-
Cash	346,945	96,118	12,877	3,065
Cash And Short Term Investments	346,945	96,118	12,877	3,065
Common Stock	7	1	1	1
Common Stock Shares Outstanding	58,496	55,216	45,951	45,552
Common Stock Total Equity	7	-	-	-
Inventory	9,769	-	-	-
Liabilities And Stockholders Equity	391,453	105,614	14,104	3,220
Long Term Debt	-	-	1,425	14,931
Net Debt	-340,668	-96,118	-11,452	11,866
Net Invested Capital	340,607	-151,168	-65,300	-10,426
Net Receivables	15,306	-	-	-
Net Tangible Assets	340,607	-151,168	-66,725	-25,357
Net Working Capital	335,524	87,555	6,313	-1,327
Non Current Assets Total	9,320	4,104	465	18
Non Current Liabilities Other	4,237	35	-	-
Non Current Liabilities Total	4,237	239,386	73,503	24,048
Non Currrent Assets Other	1,185	3,630	314	18
Other Assets	-	189	314	18
Other Current Assets	10,113	8,833	762	137
Other Current Liab	-2,040	13,024	3,713	2,334
Other Liab	-	35	16	1,442
Other Stockholder Equity	303,453	4,667	1,188	276
Property Plant And Equipment Net	8,135	474	151	-
Property Plant Equipment	2,611	474	151	-
Retained Earnings	-354,220	-155,845	-67,914	-25,634
Retained Earnings Total Equity	-354,220	-	-	-
Short Long Term Debt Total	6,277	-	1,425	14,931
Short Term Debt	2,040	-	-	-
Short Term Investments	284,419	45,927	-	-
Total Assets	391,453	105,614	14,104	3,220
Total Current Assets	382,133	101,510	13,639	3,202
Total Current Liabilities	46,609	17,396	7,326	4,529
Total Liab	50,846	256,782	80,829	28,577
Total Stockholder Equity	340,607	-151,168	-66,725	-25,357

	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31
Accounts Payable	10,770	46,609	7,052	8,117	10,045	4,372	3,026	-	-	3,613
Accumulated Other Comprehensive Income	25	-86	-725	-196	-151	9	-1	-	-	-
Capital Lease Obligations	5,787	6,277	6,758	7,074	7,191	-	-	-	-	-
Capital Stock	7	7	6	6	6	1	1	-	-	-
Capital Surpluse	705,263	694,906	456,263	450,739	444,784	-	-	-	-	-
Cash	114,563	346,945	107,734	67,440	110,403	50,191	76,677	-	-	12,877
Cash And Short Term Investments	345,674	346,945	162,593	206,681	255,205	96,118	125,702	-	-	12,877
Common Stock	7	7	6	6	6	1	1	-	-	1
Common Stock Shares Outstanding	70,864	65,417	58,533	58,276	51,604	56,466	55,216	45,951	45,951	45,951
Common Stock Total Equity	7	7	6	6	6	-	-	-	-	-
Inventory	23,148	9,769	563	-	-	-	-	-	-	-
Liabilities And Stockholders Equity	407,958	391,453	181,443	225,240	274,438	-133,737	130,460	-	-	14,104
Long Term Debt	-	-	-	-	-	-	-	-	-	1,425
Net Debt	-108,776	-340,668	-100,976	-60,366	-103,212	-50,191	-76,414	-	-	-11,452
Net Invested Capital	352,648	340,607	144,028	192,789	240,946	-151,168	-123,807	-	-	-65,300
Net Receivables	17,555	15,306	137	-	-	-	-	-	-	-
Net Tangible Assets	352,648	340,607	144,028	192,789	240,946	-151,168	-	-	-66,725	-66,725
Net Working Capital	349,603	335,524	139,552	188,975	237,782	87,555	114,796	-	-	6,313
Non Current Assets Total	8,832	9,320	9,244	9,101	8,950	663	518	-	-	465
Non Current Liabilities Other	3,694	4,237	4,768	5,287	5,786	-	-	-	-	-
Non Current Liabilities Total	5,787	4,237	4,768	5,287	5,786	35	239,384	-	-	73,503
Non Currrent Assets Other	1,185	1,185	1,175	875	875	189	189	-	-	314
Other Assets	-	-	1,175	9,101	875	189	-	-	-	314
Other Current Assets	12,749	10,113	8,906	9,458	10,283	8,833	4,240	-	-	762
Other Current Liab	36,660	-2,040	23,605	17,260	16,256	13,024	11,857	-	-	3,713
Other Liab	-	-	-	7,074	-	35	-	-	-	16
Other Stockholder Equity	297,305	694,906	274,820	225,499	444,784	4,667	3,431	-	-	1,188
Property Plant And Equipment Net	7,647	8,135	8,069	8,226	8,075	474	329	-	-	151
Property Plant Equipment	12,632	2,611	8,069	1,857	1,290	474	-	-	-	151
Retained Earnings	-352,647	-354,220	-311,516	-257,760	-203,693	-155,845	-127,501	-	-	-67,914
Retained Earnings Total Equity	-352,647	-354,220	-311,516	-257,760	-203,693	-	-	-	-	-
Short Long Term Debt	-	-	-	-	-	-	263	-	-	-
Short Long Term Debt Total	5,787	6,277	6,758	7,074	7,191	-	263	-	-	1,425
Short Term Debt	2,093	2,040	1,990	1,787	1,405	-	263	-	-	-
Short Term Investments	231,111	284,419	54,859	139,241	144,802	45,927	49,025	-	-	-
Total Assets	407,958	391,453	181,443	225,240	274,438	105,614	130,460	-	-	14,104
Total Current Assets	399,126	382,133	172,199	216,139	265,488	104,951	129,942	-	-	13,639
Total Current Liabilities	49,523	46,609	32,647	27,164	27,706	17,396	15,146	-	-	7,326
Total Liab	55,310	50,846	37,415	32,451	33,492	17,431	254,530	-	-	80,829
Total Stockholder Equity	352,648	340,607	144,028	192,789	240,946	-151,168	-124,070	-	-	-66,725

Cash Flow

Currency in USD. All numbers in thousands.

	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Begin Period Cash Flow	50,380	13,066	3,091	13,110
Capital Expenditures	2,526	353	151	151
Cash And Cash Equivalents Changes	12,930	-	-	-
Cash Flows Other Operating	21,093	-	-	-
Change In Cash	12,865	37,314	9,975	-10,019
Change In Working Capital	-1,641	4,595	2,599	3,504
Change Receivables	-14,819	-	-	-
Change To Account Receivables	-15,306	-	-	-
Change To Inventory	-9,769	-	-	-
Change To Liabilities	1,854	670	1,418	1,280
Change To Netincome	21,714	8,485	2,983	-475
Change To Operating Activities	-	3,925	1,181	2,224
Depreciation	487	52	1	1
End Period Cash Flow	63,245	50,380	13,066	3,091
Free Cash Flow	-182,397	-75,152	-36,848	-10,687
Investments	-236,462	-46,406	-46,053	-46,053
Issuance Of Capital Stock	432,447	135,000	29,958	0
Net Borrowings	-	25,896	16,817	641
Net Income	-198,375	-87,931	-42,280	-13,716
Other Cashflows From Financing Activities	-658	158,769	-151	668
Other Non Cash Items	-2,056	5,349	2,740	-583
Sale Purchase Of Stock	434,636	-	-	-
Stock Based Compensation	21,714	3,136	243	108
Total Cash From Financing Activities	431,789	158,506	46,823	668
Total Cash From Operating Activities	-179,871	-74,799	-36,697	-10,687
Total Cashflows From Investing Activities	-238,988	-46,406	-151	-151

	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31
Begin Period Cash Flow	63,245	108,453	67,859	110,822	50,380	76,866	15,284	26,336	13,066	20,927
Capital Expenditures	250	620	459	1,105	342	186	153	186	14	151
Cash And Cash Equivalents Changes	51,962	-45,715	40,963	-42,828	60,510	-	-	-	-	-
Cash Flows Other Operating	-2,937	13,221	6,927	3,179	-2,234	-	-	-	-	-
Change In Cash	52,037	-45,208	40,594	-42,963	60,442	-26,486	61,582	-11,052	13,270	-7,861
Change In Working Capital	-11,447	-11,406	5,078	1,902	2,785	-1,111	1,442	4,898	-634	-418
Change Receivables	-1,996	-14,621	-185	-12	-1	-	-	-	-	-
Change To Account Receivables	-2,249	-15,169	-137	-137	-137	-137	-	-	-	-
Change To Inventory	-13,303	-9,206	-563	-563	-563	-563	-	-	-	-
Change To Liabilities	6,789	-800	-1,101	-1,265	5,020	1,386	-	-1,049	177	466
Change To Netincome	7,501	6,091	5,435	5,707	4,392	1,189	-	3,967	2,504	121
Change To Operating Activities	-	-	6,879	3,167	-2,235	-2,497	-	5,947	-811	-884
Depreciation	204	182	165	105	35	22	10	10	10	1
End Period Cash Flow	115,282	63,245	108,453	67,859	110,822	50,380	76,866	15,284	26,336	13,066
Free Cash Flow	-5,322	-50,317	-43,537	-47,567	-40,976	-28,430	-21,018	-13,047	-12,657	-9,039
Investments	56,244	-227,560	84,500	5,567	-98,969	2,814	-49,206	3,000	3,000	3,000
Issuance Of Capital Stock	0	231,550	0	0	200,897	209	132,721	2,070	-	-
Net Borrowings	-	-	-	-	-	-263	-	-263	26,159	1,162
Net Income	1,573	-42,704	-53,756	-54,067	-47,848	-87,931	-23,142	-21,922	-14,523	-8,592
Other Cashflows From Financing Activities	1,040	612	84,041	-828	-442	-1,065	131,651	1,993	26,190	1,178
Other Non Cash Items	-2,903	-1,860	-89	-109	2	59,685	23	3,310	1,918	0
Sale Purchase Of Stock	3,539	233,491	-	248	200,897	-	-	-	-	-
Stock Based Compensation	7,501	6,091	5,524	5,707	4,392	1,091	802	657	586	121
Total Cash From Financing Activities	1,040	232,162	199,627	-828	200,455	-1,065	131,651	1,993	25,927	1,178
Total Cash From Operating Activities	-5,072	-49,697	-43,078	-46,462	-40,634	-28,244	-20,865	-13,047	-12,643	-8,888
Total Cashflows From Investing Activities	55,994	-228,180	84,041	4,462	-99,311	2,814	-	2,814	-14	-151

Income Statement

Currency in USD. All numbers in thousands.

	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Cost Of Revenue	2,993	-	-	-
Depreciation And Amortization	8,518	-5,191	284	175
Ebit	-201,341	-82,688	-39,005	-13,554
Ebitda	-201,341	-82,688	-38,721	-13,379
Gross Profit	19,237	-	-	-
Income Before Tax	-197,601	-87,931	-42,280	-13,716
Income Tax Expense	774	-36	1,270	-1,114
Interest Expense	4,291	36	2,288	1,276
Interest Income	4,291	36	14	176
Net Income	-198,375	-87,895	-43,550	-12,602
Net Income Applicable To Common Shares	-198,375	-87,931	-42,280	-13,716
Net Income From Continuing Ops	-198,375	-87,931	-42,280	-13,716
Net Interest Income	4,291	36	-2,274	-1,100
Non Operating Income Net Other	3,740	-	-	-
Operating Income	-201,341	-82,688	-39,005	-13,554
Other Operating Expenses	223,571	82,688	39,005	13,554
Reconciled Depreciation	487	52	1	0
Research Development	93,450	44,040	24,594	11,899
Selling General Administrative	127,128	38,933	15,061	3,081
Tax Provision	774	-	-	-
Total Operating Expenses	220,578	82,688	39,005	13,554
Total Other Income Expense Net	3,740	-5,243	-3,275	-162
Total Revenue	22,230	0	0	0

	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31
Cost Of Revenue	5,283	2,821	172	-	-	-	0	-	-	-
Depreciation And Amortization	-	5,807	165	105	35	-59,594	10	10	10	2
Ebit	1,403	-44,593	-54,681	-54,253	-47,814	-28,315	-22,918	-18,587	-12,868	-8,592
Ebitda	-2,053	-44,593	-54,516	-54,148	-47,779	-87,909	-22,908	-18,577	-12,858	-8,590
Gross Profit	66,145	19,064	173	-	-	-	0	-	-	-
Income Before Tax	1,403	-42,125	-53,881	-53,893	-47,702	-87,931	-23,142	-21,922	-14,523	-8,592
Income Tax Expense	-170	579	-125	174	146	-30	221	3,334	1,653	-
Interest Expense	3,456	3,157	601	402	131	30	3	1	2	1
Interest Income	3,718	3,157	601	402	131	30	3	1	2	0
Net Income	1,573	-42,704	-53,756	-54,067	-47,848	-87,901	-23,363	-25,256	-16,176	-8,592
Net Income Applicable To Common Shares	1,573	-42,704	-53,756	-54,067	-47,848	-28,344	-	-21,922	-14,523	-8,592
Net Income From Continuing Ops	1,573	-42,704	-53,756	-54,067	-47,848	-28,344	-23,142	-21,922	-14,523	-8,592
Net Interest Income	3,718	3,157	601	402	131	30	3	1	2	-1
Non Operating Income Net Other	3,456	2,468	800	360	112	-	-	-	-	-
Operating Income	-2,053	-44,593	-54,681	-54,253	-47,814	-28,315	-22,918	-18,587	-12,868	-8,592
Other Operating Expenses	73,481	66,478	55,026	54,253	47,814	28,315	22,918	18,587	12,868	8,592
Reconciled Depreciation	204	182	165	105	35	22	10	10	10	1
Research Development	24,192	22,813	24,914	24,259	21,464	44,040	12,853	10,929	6,864	5,013
Selling And Marketing Expenses	-	15,500	-	-	-	-	-	-	-	-
Selling General Administrative	44,006	56,344	29,940	29,994	26,350	38,933	10,350	7,658	6,004	3,929
Tax Provision	-170	579	-125	174	146	-	0	0	0	-
Total Operating Expenses	68,198	63,657	54,854	54,253	47,814	28,315	22,918	18,587	12,868	8,592
Total Other Income Expense Net	3,456	2,468	800	360	112	-59,616	-224	-3,335	-1,655	1
Total Revenue	71,428	21,885	345	0	0	0	0	0	0	0

Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue	22,230
Cost of Revenue	-2,993
Gross Profit	19,237	19,237

Operating Income (+$)
Gross Profit	19,237
Operating Expense	-220,578
Operating Income	-201,341	-201,341

Operating Expense (+$)
Research Development	93,450
Selling General Administrative	127,128
Selling And Marketing Expenses	-
Operating Expense	220,578	220,578

Net Interest Income (+$)
Interest Income	4,291
Interest Expense	-4,291
Other Finance Cost	-4,291
Net Interest Income	4,291

Pretax Income (+$)
Operating Income	-201,341
Net Interest Income	4,291
Other Non-Operating Income Expenses	3,740
Income Before Tax (EBT)	-197,601	-205,081 EBIT - interestExpense = -205,632 -197,601 -194,084
Interest Expense	4,291
Earnings Before Interest and Taxes (EBIT)	-201,341	-193,310
Earnings Before Interest and Taxes (EBITDA)	-201,341

After tax Income (+$)
Income Before Tax	-197,601
Tax Provision	-774
Net Income From Continuing Ops	-198,375	-198,375
Net Income	-198,375
Net Income Applicable To Common Shares	-198,375

Non-recurring Events
Discontinued Operations	-
Extraordinary Items	-
Effect of Accounting Charges	-
Other Items	-
Non Recurring	-
Other Operating Expenses	223,571
Total Other Income/Expenses Net	3,740	-8,031

Technicals of Amylyx

1. Trend Indicators

1.1 Moving Averages

Shows the moving average of the selected period.

Moving averages are lagging trend indicators.
There are many types of moving averages.
Moving averages are also used within other indicators.

Directionalities and relatives.

Moving Average	Amount of candles	Trend	Price +/-	vs. MA 50	vs. MA 100	vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Shows the moving average of the selected period.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

There are various kinds of moving averages:

Simple moving average (SMA);
Exponential moving average (EMA);
Smoothed moving average (SMMA);
Linear weighted moving average (LWMA).

The moving average looks at a certain period of time and it calculates the price average. The various types of averages are using various formulas. Don’t worry, you don’t have to memorize any formula. All moving averages are calculated automatically by basically every charting software you use. But it’s good to know how moving averages are actually calculated.

Simple moving average

SMA is calculated by summing up the price closures of the selected period. The price is then divided by the selected period. For example, when using the 21 day moving average you sum up all the closing prices for each day and divide that by 21. The result is a line on the chart representing the average. Because it’s an average in the selected timeframe, the trend is always lagging. An moving average looks like this on the chart:

Source: Tradingview.com

In this case, the blue line represents a 21 day moving average. Because the average is based on results from the past, the indicator will always lag behind. For example, when price would suddenly go up, the moving average won't immediately follow.

All other moving averages discussed below look the same on the chart. The only difference is that the line will move in different directions based on the maths behind the used indicators and the amount of days used to determine the average.

Exponential moving average

The EMA gives more weight to the latest closing prices by giving them more value in the equation. EMA is calculated by adding a certain percentage to the latest closing prices:

EMA = (CLOSE (i) * P) + (EMA (i - 1) * (1 - P))

Where:

CLOSE (i) = current period close price.
EMA (i - 1) = value of the Moving Average of a preceding period.
P = the percentage of using the price value.

Smoothed moving average

A smoothed moving average is an exponential moving average with a long lookback period. Older prices are reduced in weight but are never left out in the calculation. Unlike SMA and EMA where prices are removed when they are beyond the selected period. SMMA is a combination of the SMA and EMA. The main advantage is that it smooths out fluctuations in price.

Linear weighted moving average

The LWMA gives the latest price the highest weight and then lineary scales down with each price before that. The result is that the LWMA reacts quicker to changes in price than the SMA or EMA. The formula:

LWMA = ((Pn∗W1)+(Pn−1∗W2)+(Pn−2∗W3)...) / ∑W

Where:

P = Price for the period.
n = The most recent period, n-1 is the prior period, and n-2 is two periods prior.
W = The assigned weight to each period, with the highest weight going first and then descending linearly based on the number of periods being used.

Moving averages are widely used by many traders. Which moving average you need depends on your trading strategy. Common practise is using a combination of multiple periods. For example, the EMA21, EMA50, EMA100 and EMA200. How does that look on a chart:

Source: Tradingview.com

The lowest (purple) line on the chart represents the EMA200 then following up the EMA100, EMA50 and EMA21.

You can use moving averages to determine a trend. The 200 moving average is mostly used as a baseline for determining the current trend:

When the 200 moving average is moving up it is considered a bullish trend.
When the 200 moving average is down it is considered a bearish trend.
When moving averages are flatlined, there is no clear trend so you should look for market structure, consolidation or trend reversals. Depending on how you want to trade.

This is not set in stone. Most trading strategies use multiple moving averages each with different settings. While one strategy might use the EMA20, the other uses the SMA21. There can be hundreds of different variations. Moving averages can also be used as support and resistance. More often than not, prices will bounce on moving averages.

Amylyx Pharmaceuticals Inc Daily Moving Averages Chart

1.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

MACD is a lagging momentum indicator.
Uses two moving averages.
Can show buy or sell signals based on momentum.
Can show overbought. and oversold. levels.

Let's take a look of the Moving Average Convergence/Divergence (MACD) of Amylyx Pharmaceuticals Inc:

Amylyx Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart

1.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index).

The ADX helps you determine the strength of a trend. Let's take a look of the ADX of Amylyx Pharmaceuticals Inc:

The ADX is .
The ADX is declining, there is no upcoming trend indication. -1
The +DI is lower than the -DI. The current trend is down. -2

Amylyx Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart

1.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

Parabolic SAR (stop and reverse) is a lagging trend indicator.
Shows the current trend.
Shows potential entry signals.
Shows potential exit signals.
Can be used to place trailing stoplosses..

The price has crossed the Parabolic SAR to the upside. The trend is reversing to an up trend. +1

Amylyx Pharmaceuticals Inc Daily Parabolic SAR Chart

2. Momentum Indicators

2.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

Leading momentum indicator, meaning the signals are instant.
Ranges between 0 and 100.
Above 70 is considered overbought.
Below 30 is considered oversold.
Above or below 50 can also be used to determine price trend or support and resistance.
RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
Can be used in many different ways

The RSI is below 50. -1
The RSI is below 30 and oversold. +2

Measures the speed and change of price movements.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

The RSI measures the magnitude of recent price changes to determine if the asset is overbought or oversold.

Overbought (RSI above 70) means that the trading price is above its intrinsic value. This might indicate a sell or short signal.
Oversold (RSI below 30) means that the trading price is below its intrinsic value. This might indicate a buy or long signal.
RSI levels above or below 50 can also be used to determine a trend.
RSI divergence looks at a deviation between RSI and price movement.
Can be used in many different ways.

Original usage

Keep in mind that almost every indicator can be used in different ways. Even beyond the orginal settings. The relative strength index was developed by J. Welles Wilder. Wilder recommended a smoothing period of 14 days. That means a 14 day moving average (read more about this setting below). Another quote from the wikipedia page:

Wilders also considers the RSI 50 line as both support and resistance. I recommend to always read the original settings first before using an indicator. Many traders and websites are using their own version of the indicator which might be confusing.

How you can use RSI (Divergence)

First and foremost, there is no real right or wrong usage of the RSI indicator. You can use it in any way you want. Wilder recommends using a 14 day average but you can make it 50 or 100 if you like. Just keep in mind that using an indicator is just part of a larger trading plan. In other words, it’s not recommended to do any trading or investing based on a single indicator like the RSI.

The RSI is measured on a scale between 0 and 100. From 30 till 0 is considered oversold. and from 70 -100 is overbought. The RSI is a leading indicator, meaning the signals are instant.

I like to use the RSI as a trend\momentum indicator and not as an overbought or oversold indicator. I use the middle (50) as the baseline. When prices go above RSI 50 the trend is bullish and can indicate long positions. When below 50 it is considered bearish and can indicate short positions. Other traders use the 70 and 30 levels as overbought/oversold depending on the used strategy. The RSI indicator looks like this:

Source: Tradingview.com

The general concensus is that an RSI above 70 indicates that the security is overbought. In other words, the price this security is trading for is to high and should come down. So if RSI hits 70 or above this might indicate a sell signal or taking a short position (expecting the price will go down). Although RSI above 70 indicates the security is trading above it's fair value, that does not mean the price will go down.

Use tradingview to add indicators

I highly recommend using tradingview to add indicators to a chart. It has all the indicators you can think off and can add them for free (up to three indicators) to any chart you want. You can see that the levels 30 and 70 are marked with a dotted line. If you want you can remove these lines or give it another colour using Tradingview. You can also adjust the moving average used. You can also find RSI indicators made by the community that include other settings like RSI divergences.

Tradingview

Use Tradingview to (back)test your strategies and add hundreds of indicators created by the community.

View tool on Tradingview.com

RSI divergence

RSI is not only used to determine momentum but can also spot reversals or continuations of the trend. A reversal means that the trend is going in the opposite direction. From bullish to bearish or from bearish to bullish. These reversals can be spotted by looking at the price and the direction of the RSI. When the price is going up but the RSI is going down that means there is a divergence. This is also the case when RSI goes up but price is going down.

There are four types of divergences:

Regular bullish divergence
Regular bearish divergence
Hidden bullish divergence
Hidden bearish divergence

Regular bullish divergence

With a regular bullish divergence, the price is making lower highs but the oscillator (in this case the RSI) is making higher lows. A regular bullish divergence might indicate the end of the current trend. You’ll see regular bullish divergences mostly at the end of a downtrend. But that does not mean that every regular bullish divergence is a trend reversal.

Price is making lower highs
RSI is making higher lows
Indicating bullish reversal (price might go up)

Source: Tradingview.com

Regular bearish divergence

With a regular bearish divergence the price is making higher highs but the oscillator (in this case the RSI) is making lower highs. This might indicate the end of an uptrend.

Price is making higher highs
RSI is making lower highs
Indicating bearish reversal

Source: Tradingview.com

Hidden bullish divergence

With a hidden bullish divergence, the price is making a higher low while the RSI is making a lower low. This might indicate bullish trend continuation.

Price is making higher lows
RSI is making lower lows
Indicating bullish continuation

Source: Tradingview.com

As you have noticed, you can have multiple divergences in a row.

Hidden bearish divergence

With a hidden bearish divergence, price is making lower highs but RSI is making higher highs. This might indicate bearish trend continuation.

Price is making lower highs
RSI making higher highs
Indicating bearish continuation

Source: Tradingview.com

You can find many cheatsheets of RSI divergences online. Search for "RSI divergence overview" and you'll find a lot of examples. You can print these to learn the various types of divergences.

Amylyx Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart

2.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

Leading momentum indicator, meaning the signals are instant.
Used to determine overbought and oversold areas much like the RSI.
Ranges between 0 and 100.
Above 80 is considered overbought.
Below 20 is considered oversold.
Consists of two lines named K and D.
K compares the highest high and lowest low on the selected price range.
The D line is a moving average of the K line.
Can be used to spot divergences

The Stochastic is below 50. -1
The Stochastic is below 30 and oversold. +2

Amylyx Pharmaceuticals Inc Daily Stochastic Oscillator Chart

2.3 Commodity Channel Index (CCI)

Amylyx Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart

2.4 Chande Momentum Oscillator (CMO)

Amylyx Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart

2.5 Williams %R

Amylyx Pharmaceuticals Inc Daily Williams %R Chart

3. Volatility Indicators

3.1 Bollinger Bands

Amylyx Pharmaceuticals Inc Daily Bollinger Bands Chart

3.2 Average True Range (ATR)

Amylyx Pharmaceuticals Inc Daily Average True Range (ATR) Chart

4. Volume Indicators

4.1 On-Balance Volume (OBV)

Amylyx Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart

4.2 Money Flow Index (MFI)

Amylyx Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

5. Summary

5.1. Notifications

Type	Notification	Date
Currently no notifications for Amylyx Pharmaceuticals Inc.

5.2. Trading Signals

Date	Indicator	Entry signal	Exit signal
2023-05-23	STOCH	LONG ENTRY	SHORT CLOSE	20 crossover to upside
2023-05-24	DMI	LONG ENTRY	SHORT CLOSE
2023-05-25	ATR	LONG ENTRY	SHORT CLOSE
	MFI	20 crossover to upside
2023-05-26	RSI	LONG ENTRY	SHORT CLOSE	30 crossover to upside
2023-05-30	CMO	SHORT ENTRY	LONG CLOSE	-50 crossover to downside
	MFI	20 crossover to downside
2023-06-01	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2023-06-02	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside

5.2. Technical Score

Let's check the technical score of Amylyx Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Open	Greater than	Close	25.310
Total			0/1 (0.0%)

Create your own Symbol Scanner

Comments

Join the conversation.

Amylyx Pharmaceuticals Inc Buy, Hold or Sell?

Let's analyse Amylyx together

Get notifications about Amylyx Pharmaceuticals Inc

Quick analysis of Amylyx (30 sec.)

1. Valuation of Amylyx (5 min.)

$25.56

$4.98

2. Growth of Amylyx (5 min.)

Is Amylyx growing?

How much money is Amylyx making?

How much money comes from the company's main activities?

3. Financial Health of Amylyx (5 min.)

4. Comparing to competitors in the Biotechnology industry (5 min.)

Industry Rankings (Biotechnology)

Fundamentals of Amylyx

Financial Health

1.1. Profitability of Amylyx Pharmaceuticals Inc.

1.1. Profitability

1.1.1. Net Profit Margin

Trends

Compared to industry (Biotechnology)

1.1.2. Return on Assets

Trends

Compared to industry (Biotechnology)

1.1.3. Return on Equity

Trends

Compared to industry (Biotechnology)

1.2. Operating Efficiency of Amylyx Pharmaceuticals Inc.

1.2. Operating Efficiency

1.2.1. Operating Margin

Trends

Compared to industry (Biotechnology)

1.2.2. Operating Ratio

Trends

Compared to industry (Biotechnology)

1.3. Liquidity of Amylyx Pharmaceuticals Inc.

1.3. Liquidity

1.3.1. Current Ratio

Trends

Compared to industry (Biotechnology)

1.3.2. Quick Ratio

Trends

Compared to industry (Biotechnology)

1.4. Solvency of Amylyx Pharmaceuticals Inc.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Trends

Compared to industry (Biotechnology)

1.4.2. Debt to Equity Ratio

Trends

Compared to industry (Biotechnology)

2. Market Valuation of Amylyx Pharmaceuticals Inc

2. Earnings Per Share

2.1. Price to Earnings Ratio

Trends

Compared to industry (Biotechnology)

2.2. Price Earnings to Growth Ratio

Trends

Compared to industry (Biotechnology)

2. Book Value per Share

2.3. Price to Book Ratio

Trends

Compared to industry (Biotechnology)

Amylyx Pharmaceuticals Inc
Buy, Hold or Sell?